Jun 23, 2014 by Michael Douglass and Dave WilliamsonCan CVS Trounce Walgreen?The two biggest pharmacy stocks in the U.S. are CVS and Walgreen; which is better?
Jun 20, 2014 by Michael Douglass and Dave WilliamsonWhy AbbVie Wants ShireShire had a great day on the market after AbbVie announced its interest in the stock.
Jun 20, 2014 by Michael Douglass and Dave WilliamsonCan This Growth Driver Push AstraZeneca Forward?The COPD and asthma space is an exciting potential area of growth for AstraZeneca -- but is it enough?
Jun 20, 2014 by Michael Douglass and Dave WilliamsonCan GlaxoSmithKline Overcome This Huge Incoming Loss?Advair won't be around forever, and already there are competitors on the market eating into its profits. How will Glaxo cope?
Jun 19, 2014 by Michael Douglass3 Key Numbers from Rite Aid's EarningsLots of people focused on earnings per share. Here's what you should focus on instead.
Jun 18, 2014 by Michael Douglass and Dave WilliamsonDown 14%: Is Endocyte a Bad News Buy?Endocyte shares had a rough day -- is now a good time to get into the stock?
Jun 17, 2014 by Michael Douglass and Dave WilliamsonUp 16%: Opportunity Knocks for GWGW Pharma's news was good -- can it keep going up?
Jun 17, 2014 by Michael Douglass and Dave WilliamsonHow Much Does This Failure Hurt Celgene?Celgene's Vidaza has had a string of bad news lately -- does this affect the Celgene investing thesis?
Jun 17, 2014 by Michael Douglass and Dave WilliamsonMedtronic and Covidien: An Attractive Investment?With the deal likely to go through, will the new combined company look attractive to investors?
Jun 16, 2014 by Michael Douglass and Dave WilliamsonCovidien Up 20%: Does This Deal Make Sense?Investors were certainly excited about the deal. But should they be?
Jun 16, 2014 by Michael Douglass and Dave WilliamsonUp 32%: Time to Buy Bluebird Bio?This biotech had a great day. Is it time to buy?
Jun 16, 2014 by Michael Douglass3 Things You Need to Know about Medtronic's Purchase of CovidienHere are three quick stats from Medtronic's acquisition of Covidien.
Jun 15, 2014 by Michael Douglass and Dave Williamson3 Stocks Obamacare Is TransformingHow these three companies are changing their business models.
Jun 15, 2014 by Michael Douglass and Dave WilliamsonRevolutionizing Health Care: Drug ATMs on Every CornerCould this new technology make it a reality?
Jun 14, 2014 by Michael Douglass and Dave WilliamsonThe Best Way to Invest in the Biotech IPO BonanzaWith all the IPOs out there, what is a Foolish investor to do? Here's how to invest smart in biotech.
Jun 14, 2014 by Michael Douglass and Dave Williamson2 Key Obamacare Trends: What You Need to KnowKeep an eye on these two key trends as we continue to study and understand the Obamacare rollout.
Jun 13, 2014 by Michael Douglass and Dave WilliamsonDown 9%: Is OncoMed a Bad News Buy?OncoMed shares had a rough day. Time to buy?
Jun 13, 2014 by Michael Douglass and Dave WilliamsonIs It Time to Buy Geron?Geron had great news this week. Time to buy?
Jun 13, 2014 by Michael Douglass and Dave Williamson3 Reasons Johnson & Johnson Is a Great Dividend Stock for New InvestorsNew to investing and looking for a great health care holding? Consider this one.
Jun 13, 2014 by Michael Douglass and Dave WilliamsonIs It Time to Buy Orexigen?Some investors might see Orexigen's pullback as a buying opportunity. Here's why we don't.
